title: Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial".
authors.affiliation: Department of Haematology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece tvassilak@med.uoa.gr.
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Vassilakopoulos
authors.affiliation: Department of Haematology, Evangelismos General Hospital, Athens, Greece.
authors.forename: John
authors.initials: J
authors.lastname: Apostolidis
authors.affiliation: Department of Haematology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: Maria K
authors.initials: MK
authors.lastname: Angelopoulou
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D000069283:Rituximab
keywords: aggressive B-cell lymphoma; first remission; randomized trial; rituximab maintenance